title: Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.
abstract: Human N-formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor (GPCR) involved in host defense and sensing cellular damage. Since structure-based ligand design for many GPCRs, including FPR1, is restricted by the lack of experimental three dimensional structures, homology modeling has been widely used to study GPCR-ligand binding. Indeed, receptor-ligand binding mode predictions can be derived from homology modeling with supporting ligand information. In the present work, we report comparative docking studies of 2-(benzimidazol-2-ylthio)-N-phenylacetamide derived FPR1 agonists, identified here and previously, with several known FPR1 peptide agonists in a FPR1 homology model that is based on the crystal structure of bovine rhodopsin. We found that the binding pocket of the most active molecules shares some common features with high affinity FPR1 peptide agonists, suggesting that they may bind to similar binding sites. Classification tree analysis led to the derivation of a good recognition model based on four amino acid descriptors for distinguishing FPR1 ligands from inactive analogs. Hence, the corresponding residues (Thr199, Arg201, Gly202, and Ala261) can be considered as markers of important areas in the ligand binding site. Concurrently, we identified several unique binding features of benzimidazole derivatives and showed that alkoxy-substituents of the benzimidazole ring are located within a FPR1 hole bounded by Thr199, Thr265, Ile268, and Leu271 or in a groove in the vicinity of Leu198, Arg201, Gly202, and Arg205. The understanding of these molecular features will likely prove beneficial in future design of novel FPR1 agonists based on the benzimidazole scaffold.
authors: Department of Chemistry, Altai State Technical University, Barnaul, Russia.
authors: Andrei I
authors: AI
authors: Khlebnikov
authors: Igor A
authors: IA
authors: Schepetkin
authors: Liliya N
authors: LN
authors: Kirpotina
authors: Lars
authors: L
authors: Brive
authors: Claes
authors: C
authors: Dahlgren
authors: Mark A
authors: MA
authors: Jutila
authors: Mark T
authors: MT
authors: Quinn
mesh_terms: D000081:Acetamides / Q000737:chemistry* / Q000494:pharmacology; D020816:Amino Acid Motifs; D000818:Animals; D001562:Benzimidazoles / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D020013:Calcium Signaling / Q000187:drug effects; D002417:Cattle; D018922:HL-60 Cells; D006801:Humans; D006860:Hydrogen Bonding; D056004:Molecular Dynamics Simulation; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D044042:Receptors, Formyl Peptide / Q000819:agonists* / Q000737:chemistry / Q000378:metabolism; D044067:Receptors, Lipoxin / Q000819:agonists / Q000737:chemistry / Q000378:metabolism; D040681:Structural Homology, Protein; D013329:Structure-Activity Relationship; D013440:Sulfides / Q000737:chemistry* / Q000494:pharmacology; D013499:Surface Properties; D013816:Thermodynamics
chemical_list: D000081:Acetamides; D001562:Benzimidazoles; C469986:FPR1 protein, human; C105101:FPR2 protein, human; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; D013440:Sulfides